Enzymotec

Company Overview

Snapshot

Founded in March 1998, Enzymotec operated with 51–200 employees and raised a total of $100.4 million across six funding rounds from eight investors. The company was acquired by Frutarom in January 2018.

Business overview

Enzymotec is a biotechnology company specializing in the development and production of biofunctional ingredients derived from lipids. These ingredients are designed to address diverse health needs, from infant nutrition to senior citizens. The company's nutrition segment focuses on lipid-based ingredients for products like infant formula and nutritional supplements, while its VAYA pharmaceutical segment produces and sells branded lipid-based medical foods for the dietary management of cardiovascular and neurological disorders. Enzymotec operates within the Health Tech & Life Sciences sector, with a focus on Pharma & Medical Biotechnology and Biomaterials & Tissue Engineering.

Strategic signal

In January 2018, Enzymotec completed its acquisition by Frutarom, a move that significantly reshaped its operational structure. Concurrently, Aker BioMarine acquired Enzymotec's krill oil business, indicating a strategic divestiture of certain assets as part of the broader integration into Frutarom. This dual transaction signals a complete strategic shift for Enzymotec, transitioning from an independent entity to a specialized subsidiary within a larger corporate framework, while also streamlining its product portfolio.

Company Intelligence Q&A

What was the most significant corporate event for Enzymotec in early 2018?

In January 2018, Enzymotec was acquired by Frutarom. This acquisition led to Enzymotec becoming a fully owned subsidiary and its subsequent delisting from NASDAQ.

What happened to Enzymotec's krill oil business after the acquisition by Frutarom?

In January 2018, Aker BioMarine acquired Enzymotec's krill oil business as part of the broader corporate restructuring following Frutarom's takeover.

When did Enzymotec go public?

Enzymotec completed an Initial Public Offering (IPO) on NASDAQ in September 2013, raising $63.5 million.

Which investors participated in Enzymotec's B Round funding in February 2009?

In February 2009, Enzymotec received B Round funding from investors including Ofer Hi-Tech.

When did Frutarom first invest in Enzymotec?

Frutarom made an investment in Enzymotec in August 2017, prior to the full acquisition in January 2018.